Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL study of semaglutide for adolescents with antipsychotic-related obesity
2024-517471-21-02Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, sponsored by Capital Region of Denmark. Primary endpoint: Study completion. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2024-517471-21-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517471-21-02.